As part of its advocacy program in the United States, ACRO submits regulatory comments to US regulators. This comment letter, submitted by ACRO to FDA in 2025 on Draft Guideline for Good Clinical Practice E6(R3) Annex 2 can be found below.
As part of its advocacy program in the United States, ACRO submits regulatory comments to US regulators. This comment letter, submitted by ACRO to FDA in 2025 on Draft Guideline for Good Clinical Practice E6(R3) Annex 2 can be found below.